The Public Health Implications of Pre-Exposure Prophylaxis for HIV Infection in High Risk Individuals
Public Deposited- Last Modified
- January 25, 2020
- Creator
-
Morse, Caryn G., MD
- Affiliation: Gillings School of Global Public Health, Public Health Leadership Program
- Abstract
- Pre-exposure prophylaxis (PrEP) is a novel approach to human immunodeficiency virus (HN) infection prevention in which antiretroviral medication is used prior to potential HN exposure to reduce the likelihood of infection. PrEP may be a useful adjunct to current prevention approaches in the absence of an effective HN vaccine or microbicide. Current and planned clinical trials seek to answer critical questions about the safety and efficacy of PrEP in at-risk populations. While these clinical trials are likely to answer many questions about the role of PrEP in HIV prevention, additional clinical, social, and ethical questions will be raised. In anticipation of the results of these trials, the public health community should act proactively to answer many of the questions surrounding the use of PrEP in populations outside the context of clinical trials. By beginning to answer the myriad of questions likely to arise with this prevention strategy now, the public health system can better prepare themselves and the communities they serve for the implementation of PrEP or other HN prevention strategies in the future.
- Date of publication
- May 2005
- DOI
- Resource type
- Rights statement
- In Copyright
- Note
- Track: HC&P
- Paper type: Research or research design
- Advisor
- Wilkin, Aimee
- Reviewer
- Williamson, William
- Degree
- Master of Public Health
- Degree granting institution
- University of North Carolina at Chapel Hill
- Graduation year
- 2005
- Language
- Deposit record
- 564d1737-ca9b-4211-9c3e-c1926665c3df
Relations
- Parents:
This work has no parents.